Competition is about to heat up in the domestic antidiabetic market, as more and more new medicines for diabetes are lining up side by side with dominant imported drugs.
Since GlaxoSmithKline (GSK) introduced its Avandia, its market share has been growing quickly, achieving 37.9 billion won in 2005 sales.
By contrast, Handok Pharm Amaryl's sales plummeted with 43.3 billion won in 2005 an...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.